MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ANTX had -$1,410K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,410K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of investments
    • Stock-based compensation expense
    • Prepaid expenses and other asset...
    • Others
Negative Cash Flow Breakdown
    • Purchases of investments
    • Net loss
    • Accrued liabilities
    • Others

Cash Flow
2025-12-31
Net loss
-35,174
Stock-based compensation expense
6,246
Net accretion of discount on investments
1,070
Prepaid expenses and other assets
-1,512
Accounts payable
-296
Accrued compensation
742
Accrued liabilities
-2,402
Other current liabilities
438
Other non-current liabilities
170
Net cash used in operating activities
-29,834
Purchases of investments
46,189
Maturities of investments
74,500
Net cash provided by investing activities
28,311
Proceeds from issuance of common stock under the espp
86
Proceeds from exercise of stock options
27
Net cash provided by financing activities
113
Net (decrease) increase in cash and cash equivalents
-1,410
Cash and cash equivalents at the beginning of the period
21,351
Cash and cash equivalents at the end of the period
19,941
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of investments$74,500K Proceeds from issuance ofcommon stock under the...$86K Proceeds from exercise ofstock options$27K Net cash provided byinvesting activities$28,311K Net cash provided byfinancing activities$113K Canceled cashflow$46,189K Net (decrease)increase in cash and cash...-$1,410K Canceled cashflow$28,424K Stock-based compensationexpense$6,246K Prepaid expenses andother assets-$1,512K Accrued compensation$742K Other currentliabilities$438K Other non-currentliabilities$170K Purchases of investments$46,189K Net cash used inoperating activities-$29,834K Canceled cashflow$9,108K Net loss-$35,174K Accrued liabilities-$2,402K Net accretion ofdiscount on investments$1,070K Accounts payable-$296K

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics, Inc. (ANTX)